Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hung Su

Showing results (361-370 of 394) with videos related to

Pageof 40
Sort By:
Acta Cardiologica Sinica|January 23, 2023
Referral, Diagnosis, and Pharmacological Management of Peripheral Artery Disease: Perspectives from TaiwanJen-Kuang Lee, I-Chang Hsieh, Chun-Hung Su, et al.
Journal of Gastroenterology and Hepatology|April 2, 2019
Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysisChen-Hua Liu, Yu-Lueng Shih, Sheng-Shun Yang, et al.
Scientific Reports|September 14, 2018
Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational studyChen-Hua Liu, Yi-Jie Huang, Sien-Sing Yang, et al.
Alimentary Pharmacology & Therapeutics|February 21, 2025
Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral-Induced Cure of Hepatitis C Virus InfectionYu-Ping Chang, Ji-Yuh Lee, Chi-Yi Chen, et al.
Liver Cancer|May 14, 2020
Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral TherapyTai-Chung Tseng, Cheng-Yuan Peng, Yao-Chun Hsu, et al.
JHEP Reports : Innovation in Hepatology|April 19, 2021
Whole genome deep sequencing analysis of viral quasispecies diversity and evolution in HBeAg seroconvertersSu-Ru Lin, Ta-Yu Yang, Cheng-Yuan Peng, et al.
Journal of Medical Virology|May 15, 2024
Four weeks of off-treatment follow-up is sufficient to determine virologic responses at off-treatment week 12 in patients with hepatitis C virus infection receiving fixed-dose pangenotypic direct-acting antiviralsChen-Hua Liu, Yu-Ping Chang, Ji-Yuh Lee, et al.
Journal of Gastroenterology|April 13, 2024
Dynamic change of metabolic dysfunction-associated steatotic liver disease in patients with hepatitis C virus infection after achieving sustained virologic response with direct-acting antiviralsChen-Hua Liu, Yu-Ping Chang, Yu-Jen Fang, et al.
Scientific Reports|May 13, 2017
Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosisTung-Hung Su, Chung-Wai Shiau, Ping Jao, et al.
Journal of Gastroenterology and Hepatology|November 14, 2025
Predictive Value of Serum Mac-2 Binding Protein Glycosylation Isomer for Hepatic Fibrosis in Hepatitis C Virus-Infected Patients With Metabolic Dysfunction-Associated Steatotic Liver DiseaseYun-Chu Chen, Yu-Ping Chang, Ji-Yuh Lee, et al.
Pageof 40

Showing results (361-370 of 394) with videos related to

Sort By:
Pageof 40
Acta Cardiologica Sinica|January 23, 2023
Referral, Diagnosis, and Pharmacological Management of Peripheral Artery Disease: Perspectives from TaiwanJen-Kuang Lee, I-Chang Hsieh, Chun-Hung Su, et al.
Journal of Gastroenterology and Hepatology|April 2, 2019
Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysisChen-Hua Liu, Yu-Lueng Shih, Sheng-Shun Yang, et al.
Scientific Reports|September 14, 2018
Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational studyChen-Hua Liu, Yi-Jie Huang, Sien-Sing Yang, et al.
Alimentary Pharmacology & Therapeutics|February 21, 2025
Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral-Induced Cure of Hepatitis C Virus InfectionYu-Ping Chang, Ji-Yuh Lee, Chi-Yi Chen, et al.
Liver Cancer|May 14, 2020
Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral TherapyTai-Chung Tseng, Cheng-Yuan Peng, Yao-Chun Hsu, et al.
JHEP Reports : Innovation in Hepatology|April 19, 2021
Whole genome deep sequencing analysis of viral quasispecies diversity and evolution in HBeAg seroconvertersSu-Ru Lin, Ta-Yu Yang, Cheng-Yuan Peng, et al.
Journal of Medical Virology|May 15, 2024
Four weeks of off-treatment follow-up is sufficient to determine virologic responses at off-treatment week 12 in patients with hepatitis C virus infection receiving fixed-dose pangenotypic direct-acting antiviralsChen-Hua Liu, Yu-Ping Chang, Ji-Yuh Lee, et al.
Journal of Gastroenterology|April 13, 2024
Dynamic change of metabolic dysfunction-associated steatotic liver disease in patients with hepatitis C virus infection after achieving sustained virologic response with direct-acting antiviralsChen-Hua Liu, Yu-Ping Chang, Yu-Jen Fang, et al.
Scientific Reports|May 13, 2017
Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosisTung-Hung Su, Chung-Wai Shiau, Ping Jao, et al.
Journal of Gastroenterology and Hepatology|November 14, 2025
Predictive Value of Serum Mac-2 Binding Protein Glycosylation Isomer for Hepatic Fibrosis in Hepatitis C Virus-Infected Patients With Metabolic Dysfunction-Associated Steatotic Liver DiseaseYun-Chu Chen, Yu-Ping Chang, Ji-Yuh Lee, et al.
Pageof 40